nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—HTR6—Raloxifene—osteoporosis	0.146	0.303	CbGbCtD
Ziprasidone—CYP1A2—Estropipate—osteoporosis	0.0462	0.0961	CbGbCtD
Ziprasidone—CYP3A7—Estradiol—osteoporosis	0.0344	0.0715	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Estradiol—osteoporosis	0.0344	0.0715	CbGbCtD
Ziprasidone—CYP3A5—Estradiol—osteoporosis	0.0258	0.0536	CbGbCtD
Ziprasidone—CYP3A4—Estropipate—osteoporosis	0.0242	0.0504	CbGbCtD
Ziprasidone—CYP3A4—Calcitriol—osteoporosis	0.0242	0.0504	CbGbCtD
Ziprasidone—CYP1A2—Conjugated Estrogens—osteoporosis	0.0219	0.0455	CbGbCtD
Ziprasidone—CYP2D6—Cholecalciferol—osteoporosis	0.0196	0.0408	CbGbCtD
Ziprasidone—CYP3A4—Ergocalciferol—osteoporosis	0.0194	0.0403	CbGbCtD
Ziprasidone—CYP1A2—Estradiol—osteoporosis	0.0192	0.0399	CbGbCtD
Ziprasidone—CYP3A4—Raloxifene—osteoporosis	0.0162	0.0336	CbGbCtD
Ziprasidone—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0156	0.0325	CbGbCtD
Ziprasidone—CYP3A4—Cholecalciferol—osteoporosis	0.0125	0.026	CbGbCtD
Ziprasidone—CYP3A4—Conjugated Estrogens—osteoporosis	0.0115	0.0238	CbGbCtD
Ziprasidone—CYP3A4—Estradiol—osteoporosis	0.0101	0.0209	CbGbCtD
Ziprasidone—Vertigo—Conjugated Estrogens—osteoporosis	0.000191	0.000507	CcSEcCtD
Ziprasidone—Hyperhidrosis—Pamidronate—osteoporosis	0.000191	0.000506	CcSEcCtD
Ziprasidone—Syncope—Conjugated Estrogens—osteoporosis	0.000191	0.000506	CcSEcCtD
Ziprasidone—Hypertension—Zoledronate—osteoporosis	0.000191	0.000506	CcSEcCtD
Ziprasidone—Hypersensitivity—Alendronate—osteoporosis	0.000191	0.000506	CcSEcCtD
Ziprasidone—Headache—Etidronic acid—osteoporosis	0.00019	0.000505	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000189	0.000502	CcSEcCtD
Ziprasidone—Asthenia—Estropipate—osteoporosis	0.000189	0.0005	CcSEcCtD
Ziprasidone—Visual impairment—Estradiol—osteoporosis	0.000188	0.0005	CcSEcCtD
Ziprasidone—Anorexia—Pamidronate—osteoporosis	0.000188	0.000499	CcSEcCtD
Ziprasidone—Arthralgia—Zoledronate—osteoporosis	0.000188	0.000499	CcSEcCtD
Ziprasidone—Chest pain—Zoledronate—osteoporosis	0.000188	0.000499	CcSEcCtD
Ziprasidone—Myalgia—Zoledronate—osteoporosis	0.000188	0.000499	CcSEcCtD
Ziprasidone—Palpitations—Conjugated Estrogens—osteoporosis	0.000188	0.000499	CcSEcCtD
Ziprasidone—Insomnia—Risedronate—osteoporosis	0.000188	0.000498	CcSEcCtD
Ziprasidone—Anxiety—Zoledronate—osteoporosis	0.000187	0.000497	CcSEcCtD
Ziprasidone—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000187	0.000496	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000187	0.000495	CcSEcCtD
Ziprasidone—Paraesthesia—Risedronate—osteoporosis	0.000186	0.000494	CcSEcCtD
Ziprasidone—Asthenia—Alendronate—osteoporosis	0.000186	0.000492	CcSEcCtD
Ziprasidone—Hypersensitivity—Ibandronate—osteoporosis	0.000186	0.000492	CcSEcCtD
Ziprasidone—Cough—Conjugated Estrogens—osteoporosis	0.000186	0.000492	CcSEcCtD
Ziprasidone—Dyspnoea—Risedronate—osteoporosis	0.000185	0.000491	CcSEcCtD
Ziprasidone—Hypotension—Pamidronate—osteoporosis	0.000184	0.000489	CcSEcCtD
Ziprasidone—Dry mouth—Zoledronate—osteoporosis	0.000184	0.000488	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000184	0.000488	CcSEcCtD
Ziprasidone—Fatigue—Ethinyl Estradiol—osteoporosis	0.000184	0.000487	CcSEcCtD
Ziprasidone—Dyspepsia—Risedronate—osteoporosis	0.000183	0.000485	CcSEcCtD
Ziprasidone—Eye disorder—Estradiol—osteoporosis	0.000183	0.000485	CcSEcCtD
Ziprasidone—Tinnitus—Estradiol—osteoporosis	0.000182	0.000484	CcSEcCtD
Ziprasidone—Constipation—Ethinyl Estradiol—osteoporosis	0.000182	0.000483	CcSEcCtD
Ziprasidone—Confusional state—Zoledronate—osteoporosis	0.000182	0.000482	CcSEcCtD
Ziprasidone—Hypersensitivity—Calcitriol—osteoporosis	0.000182	0.000482	CcSEcCtD
Ziprasidone—Cardiac disorder—Estradiol—osteoporosis	0.000182	0.000481	CcSEcCtD
Ziprasidone—Arthralgia—Conjugated Estrogens—osteoporosis	0.000181	0.00048	CcSEcCtD
Ziprasidone—Chest pain—Conjugated Estrogens—osteoporosis	0.000181	0.00048	CcSEcCtD
Ziprasidone—Myalgia—Conjugated Estrogens—osteoporosis	0.000181	0.00048	CcSEcCtD
Ziprasidone—Asthenia—Ibandronate—osteoporosis	0.000181	0.000479	CcSEcCtD
Ziprasidone—Anxiety—Conjugated Estrogens—osteoporosis	0.000181	0.000479	CcSEcCtD
Ziprasidone—Nausea—Etidronic acid—osteoporosis	0.00018	0.000478	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00018	0.000477	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00018	0.000477	CcSEcCtD
Ziprasidone—Diarrhoea—Estropipate—osteoporosis	0.00018	0.000477	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Risedronate—osteoporosis	0.000179	0.000475	CcSEcCtD
Ziprasidone—Infection—Zoledronate—osteoporosis	0.000179	0.000475	CcSEcCtD
Ziprasidone—Fatigue—Risedronate—osteoporosis	0.000179	0.000475	CcSEcCtD
Ziprasidone—Insomnia—Pamidronate—osteoporosis	0.000179	0.000473	CcSEcCtD
Ziprasidone—Constipation—Risedronate—osteoporosis	0.000178	0.000471	CcSEcCtD
Ziprasidone—Angiopathy—Estradiol—osteoporosis	0.000177	0.000471	CcSEcCtD
Ziprasidone—Shock—Zoledronate—osteoporosis	0.000177	0.00047	CcSEcCtD
Ziprasidone—Paraesthesia—Pamidronate—osteoporosis	0.000177	0.00047	CcSEcCtD
Ziprasidone—Diarrhoea—Alendronate—osteoporosis	0.000177	0.00047	CcSEcCtD
Ziprasidone—Asthenia—Calcitriol—osteoporosis	0.000177	0.000469	CcSEcCtD
Ziprasidone—Nervous system disorder—Zoledronate—osteoporosis	0.000177	0.000469	CcSEcCtD
Ziprasidone—Immune system disorder—Estradiol—osteoporosis	0.000177	0.000468	CcSEcCtD
Ziprasidone—Thrombocytopenia—Zoledronate—osteoporosis	0.000177	0.000468	CcSEcCtD
Ziprasidone—Mediastinal disorder—Estradiol—osteoporosis	0.000176	0.000467	CcSEcCtD
Ziprasidone—Dyspnoea—Pamidronate—osteoporosis	0.000176	0.000467	CcSEcCtD
Ziprasidone—Tachycardia—Zoledronate—osteoporosis	0.000176	0.000467	CcSEcCtD
Ziprasidone—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000176	0.000465	CcSEcCtD
Ziprasidone—Chills—Estradiol—osteoporosis	0.000176	0.000465	CcSEcCtD
Ziprasidone—Somnolence—Pamidronate—osteoporosis	0.000176	0.000465	CcSEcCtD
Ziprasidone—Skin disorder—Zoledronate—osteoporosis	0.000175	0.000464	CcSEcCtD
Ziprasidone—Hyperhidrosis—Zoledronate—osteoporosis	0.000174	0.000462	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000174	0.000462	CcSEcCtD
Ziprasidone—Diarrhoea—Raloxifene—osteoporosis	0.000174	0.000462	CcSEcCtD
Ziprasidone—Dyspepsia—Pamidronate—osteoporosis	0.000174	0.000461	CcSEcCtD
Ziprasidone—Dizziness—Estropipate—osteoporosis	0.000174	0.000461	CcSEcCtD
Ziprasidone—Alopecia—Estradiol—osteoporosis	0.000173	0.000458	CcSEcCtD
Ziprasidone—Infection—Conjugated Estrogens—osteoporosis	0.000173	0.000457	CcSEcCtD
Ziprasidone—Diarrhoea—Ibandronate—osteoporosis	0.000172	0.000457	CcSEcCtD
Ziprasidone—Anorexia—Zoledronate—osteoporosis	0.000172	0.000456	CcSEcCtD
Ziprasidone—Decreased appetite—Pamidronate—osteoporosis	0.000172	0.000455	CcSEcCtD
Ziprasidone—Mental disorder—Estradiol—osteoporosis	0.000171	0.000454	CcSEcCtD
Ziprasidone—Dizziness—Alendronate—osteoporosis	0.000171	0.000454	CcSEcCtD
Ziprasidone—Shock—Conjugated Estrogens—osteoporosis	0.000171	0.000453	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00017	0.000452	CcSEcCtD
Ziprasidone—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00017	0.000452	CcSEcCtD
Ziprasidone—Erythema—Estradiol—osteoporosis	0.00017	0.000451	CcSEcCtD
Ziprasidone—Malnutrition—Estradiol—osteoporosis	0.00017	0.000451	CcSEcCtD
Ziprasidone—Fatigue—Pamidronate—osteoporosis	0.00017	0.000451	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Risedronate—osteoporosis	0.00017	0.00045	CcSEcCtD
Ziprasidone—Tachycardia—Conjugated Estrogens—osteoporosis	0.000169	0.000449	CcSEcCtD
Ziprasidone—Urticaria—Ethinyl Estradiol—osteoporosis	0.000169	0.000449	CcSEcCtD
Ziprasidone—Constipation—Pamidronate—osteoporosis	0.000169	0.000448	CcSEcCtD
Ziprasidone—Diarrhoea—Calcitriol—osteoporosis	0.000169	0.000448	CcSEcCtD
Ziprasidone—Skin disorder—Conjugated Estrogens—osteoporosis	0.000169	0.000447	CcSEcCtD
Ziprasidone—Hypotension—Zoledronate—osteoporosis	0.000169	0.000447	CcSEcCtD
Ziprasidone—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000168	0.000446	CcSEcCtD
Ziprasidone—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000168	0.000446	CcSEcCtD
Ziprasidone—Dizziness—Raloxifene—osteoporosis	0.000168	0.000446	CcSEcCtD
Ziprasidone—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000168	0.000445	CcSEcCtD
Ziprasidone—Flatulence—Estradiol—osteoporosis	0.000168	0.000445	CcSEcCtD
Ziprasidone—Vomiting—Estropipate—osteoporosis	0.000167	0.000443	CcSEcCtD
Ziprasidone—Dizziness—Ibandronate—osteoporosis	0.000167	0.000442	CcSEcCtD
Ziprasidone—Rash—Estropipate—osteoporosis	0.000166	0.000439	CcSEcCtD
Ziprasidone—Dermatitis—Estropipate—osteoporosis	0.000166	0.000439	CcSEcCtD
Ziprasidone—Anorexia—Conjugated Estrogens—osteoporosis	0.000166	0.000439	CcSEcCtD
Ziprasidone—Urticaria—Risedronate—osteoporosis	0.000165	0.000437	CcSEcCtD
Ziprasidone—Back pain—Estradiol—osteoporosis	0.000165	0.000437	CcSEcCtD
Ziprasidone—Headache—Estropipate—osteoporosis	0.000165	0.000437	CcSEcCtD
Ziprasidone—Vomiting—Alendronate—osteoporosis	0.000165	0.000436	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000164	0.000436	CcSEcCtD
Ziprasidone—Abdominal pain—Risedronate—osteoporosis	0.000164	0.000435	CcSEcCtD
Ziprasidone—Body temperature increased—Risedronate—osteoporosis	0.000164	0.000435	CcSEcCtD
Ziprasidone—Muscle spasms—Estradiol—osteoporosis	0.000164	0.000434	CcSEcCtD
Ziprasidone—Rash—Alendronate—osteoporosis	0.000163	0.000433	CcSEcCtD
Ziprasidone—Insomnia—Zoledronate—osteoporosis	0.000163	0.000432	CcSEcCtD
Ziprasidone—Dermatitis—Alendronate—osteoporosis	0.000163	0.000432	CcSEcCtD
Ziprasidone—Feeling abnormal—Pamidronate—osteoporosis	0.000163	0.000431	CcSEcCtD
Ziprasidone—Hypotension—Conjugated Estrogens—osteoporosis	0.000162	0.00043	CcSEcCtD
Ziprasidone—Headache—Alendronate—osteoporosis	0.000162	0.00043	CcSEcCtD
Ziprasidone—Paraesthesia—Zoledronate—osteoporosis	0.000162	0.000429	CcSEcCtD
Ziprasidone—Vomiting—Raloxifene—osteoporosis	0.000162	0.000429	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Pamidronate—osteoporosis	0.000161	0.000428	CcSEcCtD
Ziprasidone—Dyspnoea—Zoledronate—osteoporosis	0.000161	0.000426	CcSEcCtD
Ziprasidone—Rash—Raloxifene—osteoporosis	0.00016	0.000426	CcSEcCtD
Ziprasidone—Dermatitis—Raloxifene—osteoporosis	0.00016	0.000425	CcSEcCtD
Ziprasidone—Somnolence—Zoledronate—osteoporosis	0.00016	0.000425	CcSEcCtD
Ziprasidone—Vomiting—Ibandronate—osteoporosis	0.00016	0.000425	CcSEcCtD
Ziprasidone—Tremor—Estradiol—osteoporosis	0.00016	0.000423	CcSEcCtD
Ziprasidone—Headache—Raloxifene—osteoporosis	0.000159	0.000423	CcSEcCtD
Ziprasidone—Rash—Ibandronate—osteoporosis	0.000159	0.000421	CcSEcCtD
Ziprasidone—Dermatitis—Ibandronate—osteoporosis	0.000159	0.000421	CcSEcCtD
Ziprasidone—Dyspepsia—Zoledronate—osteoporosis	0.000159	0.000421	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000158	0.000419	CcSEcCtD
Ziprasidone—Headache—Ibandronate—osteoporosis	0.000158	0.000419	CcSEcCtD
Ziprasidone—Insomnia—Conjugated Estrogens—osteoporosis	0.000157	0.000416	CcSEcCtD
Ziprasidone—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000157	0.000416	CcSEcCtD
Ziprasidone—Vomiting—Calcitriol—osteoporosis	0.000157	0.000416	CcSEcCtD
Ziprasidone—Decreased appetite—Zoledronate—osteoporosis	0.000157	0.000416	CcSEcCtD
Ziprasidone—Agitation—Estradiol—osteoporosis	0.000156	0.000415	CcSEcCtD
Ziprasidone—Nausea—Estropipate—osteoporosis	0.000156	0.000414	CcSEcCtD
Ziprasidone—Body temperature increased—Pamidronate—osteoporosis	0.000156	0.000414	CcSEcCtD
Ziprasidone—Abdominal pain—Pamidronate—osteoporosis	0.000156	0.000414	CcSEcCtD
Ziprasidone—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000156	0.000413	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000156	0.000413	CcSEcCtD
Ziprasidone—Angioedema—Estradiol—osteoporosis	0.000156	0.000413	CcSEcCtD
Ziprasidone—Rash—Calcitriol—osteoporosis	0.000156	0.000412	CcSEcCtD
Ziprasidone—Fatigue—Zoledronate—osteoporosis	0.000155	0.000412	CcSEcCtD
Ziprasidone—Dermatitis—Calcitriol—osteoporosis	0.000155	0.000412	CcSEcCtD
Ziprasidone—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000155	0.00041	CcSEcCtD
Ziprasidone—Headache—Calcitriol—osteoporosis	0.000155	0.00041	CcSEcCtD
Ziprasidone—Somnolence—Conjugated Estrogens—osteoporosis	0.000154	0.000409	CcSEcCtD
Ziprasidone—Constipation—Zoledronate—osteoporosis	0.000154	0.000409	CcSEcCtD
Ziprasidone—Nausea—Alendronate—osteoporosis	0.000154	0.000408	CcSEcCtD
Ziprasidone—Hypersensitivity—Risedronate—osteoporosis	0.000153	0.000406	CcSEcCtD
Ziprasidone—Vertigo—Estradiol—osteoporosis	0.000153	0.000406	CcSEcCtD
Ziprasidone—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000153	0.000405	CcSEcCtD
Ziprasidone—Asthenia—Ethinyl Estradiol—osteoporosis	0.000153	0.000405	CcSEcCtD
Ziprasidone—Syncope—Estradiol—osteoporosis	0.000153	0.000405	CcSEcCtD
Ziprasidone—Nausea—Raloxifene—osteoporosis	0.000151	0.000401	CcSEcCtD
Ziprasidone—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000151	0.0004	CcSEcCtD
Ziprasidone—Palpitations—Estradiol—osteoporosis	0.00015	0.000399	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00015	0.000397	CcSEcCtD
Ziprasidone—Fatigue—Conjugated Estrogens—osteoporosis	0.00015	0.000397	CcSEcCtD
Ziprasidone—Nausea—Ibandronate—osteoporosis	0.00015	0.000397	CcSEcCtD
Ziprasidone—Loss of consciousness—Estradiol—osteoporosis	0.00015	0.000397	CcSEcCtD
Ziprasidone—Asthenia—Risedronate—osteoporosis	0.000149	0.000395	CcSEcCtD
Ziprasidone—Feeling abnormal—Zoledronate—osteoporosis	0.000149	0.000394	CcSEcCtD
Ziprasidone—Cough—Estradiol—osteoporosis	0.000149	0.000394	CcSEcCtD
Ziprasidone—Constipation—Conjugated Estrogens—osteoporosis	0.000148	0.000394	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Zoledronate—osteoporosis	0.000147	0.000391	CcSEcCtD
Ziprasidone—Hypertension—Estradiol—osteoporosis	0.000147	0.00039	CcSEcCtD
Ziprasidone—Nausea—Calcitriol—osteoporosis	0.000147	0.000389	CcSEcCtD
Ziprasidone—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000146	0.000386	CcSEcCtD
Ziprasidone—Hypersensitivity—Pamidronate—osteoporosis	0.000145	0.000386	CcSEcCtD
Ziprasidone—Chest pain—Estradiol—osteoporosis	0.000145	0.000384	CcSEcCtD
Ziprasidone—Arthralgia—Estradiol—osteoporosis	0.000145	0.000384	CcSEcCtD
Ziprasidone—Myalgia—Estradiol—osteoporosis	0.000145	0.000384	CcSEcCtD
Ziprasidone—Anxiety—Estradiol—osteoporosis	0.000144	0.000383	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000144	0.000382	CcSEcCtD
Ziprasidone—Urticaria—Zoledronate—osteoporosis	0.000143	0.00038	CcSEcCtD
Ziprasidone—Body temperature increased—Zoledronate—osteoporosis	0.000143	0.000378	CcSEcCtD
Ziprasidone—Abdominal pain—Zoledronate—osteoporosis	0.000143	0.000378	CcSEcCtD
Ziprasidone—Diarrhoea—Risedronate—osteoporosis	0.000142	0.000377	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000142	0.000376	CcSEcCtD
Ziprasidone—Dry mouth—Estradiol—osteoporosis	0.000142	0.000376	CcSEcCtD
Ziprasidone—Asthenia—Pamidronate—osteoporosis	0.000142	0.000376	CcSEcCtD
Ziprasidone—Dizziness—Ethinyl Estradiol—osteoporosis	0.000141	0.000373	CcSEcCtD
Ziprasidone—Confusional state—Estradiol—osteoporosis	0.00014	0.000372	CcSEcCtD
Ziprasidone—Infection—Estradiol—osteoporosis	0.000138	0.000366	CcSEcCtD
Ziprasidone—Urticaria—Conjugated Estrogens—osteoporosis	0.000138	0.000366	CcSEcCtD
Ziprasidone—Dizziness—Risedronate—osteoporosis	0.000137	0.000364	CcSEcCtD
Ziprasidone—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000137	0.000364	CcSEcCtD
Ziprasidone—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000137	0.000364	CcSEcCtD
Ziprasidone—Shock—Estradiol—osteoporosis	0.000137	0.000363	CcSEcCtD
Ziprasidone—Nervous system disorder—Estradiol—osteoporosis	0.000136	0.000361	CcSEcCtD
Ziprasidone—Tachycardia—Estradiol—osteoporosis	0.000136	0.00036	CcSEcCtD
Ziprasidone—Vomiting—Ethinyl Estradiol—osteoporosis	0.000135	0.000359	CcSEcCtD
Ziprasidone—Diarrhoea—Pamidronate—osteoporosis	0.000135	0.000358	CcSEcCtD
Ziprasidone—Skin disorder—Estradiol—osteoporosis	0.000135	0.000358	CcSEcCtD
Ziprasidone—Hyperhidrosis—Estradiol—osteoporosis	0.000134	0.000356	CcSEcCtD
Ziprasidone—Rash—Ethinyl Estradiol—osteoporosis	0.000134	0.000356	CcSEcCtD
Ziprasidone—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000134	0.000356	CcSEcCtD
Ziprasidone—Headache—Ethinyl Estradiol—osteoporosis	0.000133	0.000354	CcSEcCtD
Ziprasidone—Hypersensitivity—Zoledronate—osteoporosis	0.000133	0.000352	CcSEcCtD
Ziprasidone—Vomiting—Risedronate—osteoporosis	0.000132	0.00035	CcSEcCtD
Ziprasidone—Rash—Risedronate—osteoporosis	0.000131	0.000347	CcSEcCtD
Ziprasidone—Dermatitis—Risedronate—osteoporosis	0.000131	0.000347	CcSEcCtD
Ziprasidone—Dizziness—Pamidronate—osteoporosis	0.000131	0.000346	CcSEcCtD
Ziprasidone—Headache—Risedronate—osteoporosis	0.00013	0.000345	CcSEcCtD
Ziprasidone—Asthenia—Zoledronate—osteoporosis	0.000129	0.000343	CcSEcCtD
Ziprasidone—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000128	0.000339	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000127	0.000336	CcSEcCtD
Ziprasidone—Nausea—Ethinyl Estradiol—osteoporosis	0.000127	0.000335	CcSEcCtD
Ziprasidone—Insomnia—Estradiol—osteoporosis	0.000126	0.000333	CcSEcCtD
Ziprasidone—Vomiting—Pamidronate—osteoporosis	0.000126	0.000333	CcSEcCtD
Ziprasidone—Paraesthesia—Estradiol—osteoporosis	0.000125	0.000331	CcSEcCtD
Ziprasidone—Asthenia—Conjugated Estrogens—osteoporosis	0.000125	0.00033	CcSEcCtD
Ziprasidone—Rash—Pamidronate—osteoporosis	0.000124	0.00033	CcSEcCtD
Ziprasidone—Dermatitis—Pamidronate—osteoporosis	0.000124	0.00033	CcSEcCtD
Ziprasidone—Dyspnoea—Estradiol—osteoporosis	0.000124	0.000329	CcSEcCtD
Ziprasidone—Headache—Pamidronate—osteoporosis	0.000124	0.000328	CcSEcCtD
Ziprasidone—Somnolence—Estradiol—osteoporosis	0.000124	0.000328	CcSEcCtD
Ziprasidone—Diarrhoea—Zoledronate—osteoporosis	0.000123	0.000327	CcSEcCtD
Ziprasidone—Nausea—Risedronate—osteoporosis	0.000123	0.000327	CcSEcCtD
Ziprasidone—Dyspepsia—Estradiol—osteoporosis	0.000122	0.000324	CcSEcCtD
Ziprasidone—Decreased appetite—Estradiol—osteoporosis	0.000121	0.00032	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Estradiol—osteoporosis	0.00012	0.000318	CcSEcCtD
Ziprasidone—Fatigue—Estradiol—osteoporosis	0.00012	0.000318	CcSEcCtD
Ziprasidone—Dizziness—Zoledronate—osteoporosis	0.000119	0.000316	CcSEcCtD
Ziprasidone—Constipation—Estradiol—osteoporosis	0.000119	0.000315	CcSEcCtD
Ziprasidone—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000119	0.000315	CcSEcCtD
Ziprasidone—Nausea—Pamidronate—osteoporosis	0.000117	0.000311	CcSEcCtD
Ziprasidone—Dizziness—Conjugated Estrogens—osteoporosis	0.000115	0.000304	CcSEcCtD
Ziprasidone—Vomiting—Zoledronate—osteoporosis	0.000115	0.000304	CcSEcCtD
Ziprasidone—Feeling abnormal—Estradiol—osteoporosis	0.000115	0.000304	CcSEcCtD
Ziprasidone—Rash—Zoledronate—osteoporosis	0.000114	0.000301	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Estradiol—osteoporosis	0.000114	0.000301	CcSEcCtD
Ziprasidone—Dermatitis—Zoledronate—osteoporosis	0.000114	0.000301	CcSEcCtD
Ziprasidone—Headache—Zoledronate—osteoporosis	0.000113	0.0003	CcSEcCtD
Ziprasidone—Vomiting—Conjugated Estrogens—osteoporosis	0.00011	0.000293	CcSEcCtD
Ziprasidone—Urticaria—Estradiol—osteoporosis	0.00011	0.000293	CcSEcCtD
Ziprasidone—Abdominal pain—Estradiol—osteoporosis	0.00011	0.000291	CcSEcCtD
Ziprasidone—Body temperature increased—Estradiol—osteoporosis	0.00011	0.000291	CcSEcCtD
Ziprasidone—Rash—Conjugated Estrogens—osteoporosis	0.000109	0.00029	CcSEcCtD
Ziprasidone—Dermatitis—Conjugated Estrogens—osteoporosis	0.000109	0.00029	CcSEcCtD
Ziprasidone—Headache—Conjugated Estrogens—osteoporosis	0.000109	0.000288	CcSEcCtD
Ziprasidone—Nausea—Zoledronate—osteoporosis	0.000107	0.000284	CcSEcCtD
Ziprasidone—Nausea—Conjugated Estrogens—osteoporosis	0.000103	0.000273	CcSEcCtD
Ziprasidone—Hypersensitivity—Estradiol—osteoporosis	0.000102	0.000271	CcSEcCtD
Ziprasidone—Asthenia—Estradiol—osteoporosis	9.97e-05	0.000264	CcSEcCtD
Ziprasidone—Diarrhoea—Estradiol—osteoporosis	9.51e-05	0.000252	CcSEcCtD
Ziprasidone—Dizziness—Estradiol—osteoporosis	9.19e-05	0.000244	CcSEcCtD
Ziprasidone—Vomiting—Estradiol—osteoporosis	8.84e-05	0.000234	CcSEcCtD
Ziprasidone—Rash—Estradiol—osteoporosis	8.76e-05	0.000232	CcSEcCtD
Ziprasidone—Dermatitis—Estradiol—osteoporosis	8.75e-05	0.000232	CcSEcCtD
Ziprasidone—Headache—Estradiol—osteoporosis	8.71e-05	0.000231	CcSEcCtD
Ziprasidone—Nausea—Estradiol—osteoporosis	8.25e-05	0.000219	CcSEcCtD
Ziprasidone—DRD4—Signaling Pathways—IGF1—osteoporosis	1.11e-05	7.82e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ACP5—osteoporosis	1.11e-05	7.77e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IRS2—osteoporosis	1.1e-05	7.76e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IGF1—osteoporosis	1.1e-05	7.72e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—POMC—osteoporosis	1.09e-05	7.68e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IRS1—osteoporosis	1.08e-05	7.6e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—LEP—osteoporosis	1.08e-05	7.59e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—ADCY5—osteoporosis	1.07e-05	7.51e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—POMC—osteoporosis	1.07e-05	7.5e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IRS1—osteoporosis	1.07e-05	7.5e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6R—osteoporosis	1.07e-05	7.49e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IRS2—osteoporosis	1.07e-05	7.49e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IRS2—osteoporosis	1.06e-05	7.45e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—MTHFR—osteoporosis	1.05e-05	7.4e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—ADCY5—osteoporosis	1.05e-05	7.39e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IGF1—osteoporosis	1.05e-05	7.39e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—ADCY5—osteoporosis	1.05e-05	7.38e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—ADCY5—osteoporosis	1.05e-05	7.37e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ADCY5—osteoporosis	1.05e-05	7.35e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—GPX1—osteoporosis	1.05e-05	7.35e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.04e-05	7.33e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ADCY5—osteoporosis	1.04e-05	7.33e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—LEP—osteoporosis	1.04e-05	7.33e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—POMC—osteoporosis	1.04e-05	7.32e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—LEP—osteoporosis	1.04e-05	7.29e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—POMC—osteoporosis	1.04e-05	7.28e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—SPP1—osteoporosis	1.03e-05	7.27e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ADCY5—osteoporosis	1.03e-05	7.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—ESR1—osteoporosis	1.03e-05	7.25e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IRS2—osteoporosis	1.03e-05	7.25e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ADCY5—osteoporosis	1.03e-05	7.24e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—POMC—osteoporosis	1.03e-05	7.22e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—TPI1—osteoporosis	1.03e-05	7.22e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—MYC—osteoporosis	1.02e-05	7.2e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—TGFB1—osteoporosis	1.02e-05	7.18e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—SPP1—osteoporosis	1.02e-05	7.15e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6R—osteoporosis	1.02e-05	7.14e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—SPP1—osteoporosis	1.02e-05	7.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IRS2—osteoporosis	1.01e-05	7.13e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—SPP1—osteoporosis	1.01e-05	7.11e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—SPP1—osteoporosis	1.01e-05	7.09e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—LEP—osteoporosis	1.01e-05	7.09e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6R—osteoporosis	1e-05	7.05e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IGF1—osteoporosis	1e-05	7.04e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—SPP1—osteoporosis	9.99e-06	7.02e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—SPP1—osteoporosis	9.96e-06	7e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—ESR1—osteoporosis	9.95e-06	7e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—LEP—osteoporosis	9.93e-06	6.98e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—ESR1—osteoporosis	9.9e-06	6.96e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IGF1—osteoporosis	9.88e-06	6.95e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ENO1—osteoporosis	9.67e-06	6.8e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—P4HB—osteoporosis	9.66e-06	6.79e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—MTHFR—osteoporosis	9.65e-06	6.78e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IRS1—osteoporosis	9.63e-06	6.77e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—ESR1—osteoporosis	9.63e-06	6.77e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	9.57e-06	6.73e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PSMA5—osteoporosis	9.53e-06	6.7e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PSMA2—osteoporosis	9.53e-06	6.7e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GAPDH—osteoporosis	9.48e-06	6.66e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—ESR1—osteoporosis	9.48e-06	6.66e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IRS2—osteoporosis	9.35e-06	6.57e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IRS1—osteoporosis	9.3e-06	6.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—POMC—osteoporosis	9.28e-06	6.52e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—SPP1—osteoporosis	9.26e-06	6.51e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IRS1—osteoporosis	9.25e-06	6.5e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—RAP1A—osteoporosis	9.23e-06	6.49e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IRS2—osteoporosis	9.2e-06	6.47e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IRS2—osteoporosis	9.18e-06	6.46e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—POMC—osteoporosis	9.17e-06	6.45e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IRS2—osteoporosis	9.15e-06	6.43e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—LEP—osteoporosis	9.15e-06	6.43e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—CYP19A1—osteoporosis	9.13e-06	6.42e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IRS2—osteoporosis	9.12e-06	6.41e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—MYC—osteoporosis	9.06e-06	6.37e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6R—osteoporosis	9.05e-06	6.36e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TGFB1—osteoporosis	9.04e-06	6.35e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IRS2—osteoporosis	9.04e-06	6.35e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IRS2—osteoporosis	9.01e-06	6.33e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—LEP—osteoporosis	9.01e-06	6.33e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IRS1—osteoporosis	9e-06	6.33e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—LEP—osteoporosis	8.99e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—LEP—osteoporosis	8.96e-06	6.3e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—POMC—osteoporosis	8.96e-06	6.3e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—LEP—osteoporosis	8.93e-06	6.28e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IGF1—osteoporosis	8.92e-06	6.27e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—POMC—osteoporosis	8.91e-06	6.26e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—IL6—osteoporosis	8.9e-06	6.26e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—IL6—osteoporosis	8.89e-06	6.25e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IRS1—osteoporosis	8.86e-06	6.23e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—LEP—osteoporosis	8.84e-06	6.22e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—IL6—osteoporosis	8.83e-06	6.21e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—LEP—osteoporosis	8.82e-06	6.2e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—ESR1—osteoporosis	8.74e-06	6.14e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6R—osteoporosis	8.74e-06	6.14e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6R—osteoporosis	8.69e-06	6.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—POMC—osteoporosis	8.67e-06	6.09e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—IL6—osteoporosis	8.65e-06	6.08e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IGF1—osteoporosis	8.61e-06	6.06e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—ESR1—osteoporosis	8.6e-06	6.04e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—ESR1—osteoporosis	8.58e-06	6.03e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IGF1—osteoporosis	8.57e-06	6.02e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ESR1—osteoporosis	8.55e-06	6.01e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—POMC—osteoporosis	8.53e-06	5.99e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ESR1—osteoporosis	8.53e-06	5.99e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—IL6—osteoporosis	8.51e-06	5.98e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6R—osteoporosis	8.45e-06	5.94e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ESR1—osteoporosis	8.44e-06	5.93e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ESR1—osteoporosis	8.42e-06	5.92e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—POMC—osteoporosis	8.42e-06	5.92e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—IL6—osteoporosis	8.4e-06	5.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IRS2—osteoporosis	8.37e-06	5.89e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IGF1—osteoporosis	8.34e-06	5.86e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6R—osteoporosis	8.32e-06	5.85e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IGF1—osteoporosis	8.2e-06	5.77e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—LEP—osteoporosis	8.19e-06	5.76e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IRS1—osteoporosis	8.17e-06	5.74e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—IL6—osteoporosis	8.04e-06	5.65e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IRS1—osteoporosis	8.03e-06	5.65e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IRS1—osteoporosis	8.02e-06	5.64e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IRS1—osteoporosis	7.99e-06	5.62e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IRS1—osteoporosis	7.97e-06	5.6e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IRS1—osteoporosis	7.89e-06	5.54e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IRS1—osteoporosis	7.87e-06	5.53e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—POMC—osteoporosis	7.86e-06	5.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ESR1—osteoporosis	7.82e-06	5.5e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—POMC—osteoporosis	7.74e-06	5.44e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CYP19A1—osteoporosis	7.73e-06	5.44e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—POMC—osteoporosis	7.72e-06	5.43e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—POMC—osteoporosis	7.71e-06	5.42e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—IL6—osteoporosis	7.7e-06	5.41e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—POMC—osteoporosis	7.7e-06	5.41e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—POMC—osteoporosis	7.67e-06	5.39e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6R—osteoporosis	7.67e-06	5.39e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—IL6—osteoporosis	7.66e-06	5.38e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—POMC—osteoporosis	7.6e-06	5.34e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—POMC—osteoporosis	7.58e-06	5.32e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IGF1—osteoporosis	7.56e-06	5.32e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—IL6—osteoporosis	7.56e-06	5.31e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6R—osteoporosis	7.55e-06	5.31e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6R—osteoporosis	7.53e-06	5.29e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6R—osteoporosis	7.51e-06	5.28e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6R—osteoporosis	7.48e-06	5.26e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ENO1—osteoporosis	7.46e-06	5.25e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ADCY5—osteoporosis	7.46e-06	5.24e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IGF1—osteoporosis	7.44e-06	5.23e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—GPX1—osteoporosis	7.43e-06	5.22e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IGF1—osteoporosis	7.43e-06	5.22e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6R—osteoporosis	7.41e-06	5.21e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IGF1—osteoporosis	7.4e-06	5.2e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6R—osteoporosis	7.39e-06	5.19e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IGF1—osteoporosis	7.38e-06	5.19e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PSMA5—osteoporosis	7.36e-06	5.17e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PSMA2—osteoporosis	7.36e-06	5.17e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IRS1—osteoporosis	7.31e-06	5.14e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IGF1—osteoporosis	7.31e-06	5.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IGF1—osteoporosis	7.29e-06	5.12e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—POMC—osteoporosis	7.04e-06	4.95e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MYC—osteoporosis	6.99e-06	4.92e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MYC—osteoporosis	6.99e-06	4.91e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TGFB1—osteoporosis	6.98e-06	4.9e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TGFB1—osteoporosis	6.97e-06	4.9e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MYC—osteoporosis	6.94e-06	4.88e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TGFB1—osteoporosis	6.92e-06	4.87e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6R—osteoporosis	6.87e-06	4.83e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—MTHFR—osteoporosis	6.86e-06	4.82e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—IL6—osteoporosis	6.82e-06	4.8e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—IL6—osteoporosis	6.81e-06	4.79e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MYC—osteoporosis	6.8e-06	4.78e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TGFB1—osteoporosis	6.78e-06	4.77e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IGF1—osteoporosis	6.77e-06	4.76e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MYC—osteoporosis	6.69e-06	4.7e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TGFB1—osteoporosis	6.67e-06	4.69e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MYC—osteoporosis	6.6e-06	4.64e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—IL6—osteoporosis	6.59e-06	4.63e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TGFB1—osteoporosis	6.58e-06	4.63e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—IL6—osteoporosis	6.55e-06	4.61e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—IL6—osteoporosis	6.37e-06	4.48e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MYC—osteoporosis	6.32e-06	4.44e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ADCY5—osteoporosis	6.32e-06	4.44e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TGFB1—osteoporosis	6.3e-06	4.43e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GPX1—osteoporosis	6.3e-06	4.43e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—IL6—osteoporosis	6.27e-06	4.41e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MYC—osteoporosis	6.02e-06	4.23e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TGFB1—osteoporosis	6.01e-06	4.22e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CYP19A1—osteoporosis	5.97e-06	4.19e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MYC—osteoporosis	5.94e-06	4.18e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TGFB1—osteoporosis	5.93e-06	4.17e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—MTHFR—osteoporosis	5.81e-06	4.08e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—IL6—osteoporosis	5.78e-06	4.07e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—IL6—osteoporosis	5.69e-06	4e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—IL6—osteoporosis	5.68e-06	3.99e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—IL6—osteoporosis	5.66e-06	3.98e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—IL6—osteoporosis	5.64e-06	3.97e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—IL6—osteoporosis	5.59e-06	3.93e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—IL6—osteoporosis	5.57e-06	3.92e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—POMC—osteoporosis	5.49e-06	3.86e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MYC—osteoporosis	5.36e-06	3.77e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TGFB1—osteoporosis	5.35e-06	3.76e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—osteoporosis	5.26e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—osteoporosis	5.25e-06	3.69e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—osteoporosis	5.22e-06	3.67e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—osteoporosis	5.18e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MYC—osteoporosis	5.18e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TGFB1—osteoporosis	5.16e-06	3.63e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MYC—osteoporosis	5.15e-06	3.62e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TGFB1—osteoporosis	5.14e-06	3.61e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—osteoporosis	5.11e-06	3.59e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—osteoporosis	5.03e-06	3.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MYC—osteoporosis	5.01e-06	3.52e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TGFB1—osteoporosis	5e-06	3.51e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—osteoporosis	4.96e-06	3.49e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MYC—osteoporosis	4.93e-06	3.47e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TGFB1—osteoporosis	4.92e-06	3.46e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ADCY5—osteoporosis	4.88e-06	3.43e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GPX1—osteoporosis	4.86e-06	3.42e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—osteoporosis	4.75e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—POMC—osteoporosis	4.65e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MYC—osteoporosis	4.55e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TGFB1—osteoporosis	4.53e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—osteoporosis	4.53e-06	3.18e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—MTHFR—osteoporosis	4.48e-06	3.15e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MYC—osteoporosis	4.47e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—osteoporosis	4.47e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MYC—osteoporosis	4.46e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TGFB1—osteoporosis	4.46e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TGFB1—osteoporosis	4.45e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MYC—osteoporosis	4.45e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TGFB1—osteoporosis	4.44e-06	3.12e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MYC—osteoporosis	4.43e-06	3.12e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TGFB1—osteoporosis	4.42e-06	3.11e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MYC—osteoporosis	4.39e-06	3.09e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TGFB1—osteoporosis	4.38e-06	3.08e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MYC—osteoporosis	4.38e-06	3.08e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TGFB1—osteoporosis	4.37e-06	3.07e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MYC—osteoporosis	4.07e-06	2.86e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	4.06e-06	2.85e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—osteoporosis	4.03e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—osteoporosis	3.89e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—osteoporosis	3.87e-06	2.72e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—osteoporosis	3.77e-06	2.65e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—osteoporosis	3.71e-06	2.61e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—POMC—osteoporosis	3.59e-06	2.52e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—osteoporosis	3.42e-06	2.4e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—osteoporosis	3.36e-06	2.36e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—osteoporosis	3.35e-06	2.36e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—osteoporosis	3.34e-06	2.35e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—osteoporosis	3.33e-06	2.34e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—osteoporosis	3.3e-06	2.32e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—osteoporosis	3.29e-06	2.31e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—osteoporosis	3.06e-06	2.15e-05	CbGpPWpGaD
